CRVO CervoMed Inc.
USHealthcareAs of 2026-08-24
Why CRVO matters now
CervoMed Inc. (CRVO) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.63 with +0.38% on the session and $24.4M in market capitalization; recent performance reads 1-month +46.71% and YTD -46.33%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-8.0M, and EPS of $-0.86. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -70.2%.
The latest indexable market news headline is "CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $9.00; recent insider activity includes BOGER JOSHUA S filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.70
P/S
121.70
EV/EBITDA
-1.04
DCF Value
$0.80
FCF Yield
-70.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-9642.1%
Net Margin
-9311.6%
ROE
-136.1%
ROA
-198.7%
ROIC
-293.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-8.0M | $-0.86 |
| Q4 2025 | $0.00 | $-8.1M | $-0.87 |
| FY 2025 | $0.00 | $-27.0M | $-2.98 |
| Q3 2025 | $322.6K | $-7.7M | $-0.84 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$9.00
Target (Median)
$9.00
Target Range
$9.00 - $9.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-4.54
CervoMed Inc., headquartered in Boston, Massachusetts, operates as a clinical-stage biotechnology firm committed to discovering, developing, and ultimately bringing to market pharmaceutical solutions for various neurodegenerative conditions. A central component of their therapeutic pipeline is neflamapimod, an innovative small molecule designed for oral administration and capable of crossing the blood-brain barrier. This compound is currently being advanced as a potential treatment for debilitating ailments such as Lewy body dementia (DLB), Alzheimer's disease, and for aiding recovery following a cerebral stroke.